Evaluation of clinical efficacy and safety of sentinel lymph node biopsy using magnetic nanoparticle and magnetic probe

Evaluation of clinical efficacy and safety of sentinel lymph node biopsy using magnetic nanoparticle and magnetic probe - Evaluation of clinical efficacy and safety of sentinel lymph node biopsy using magnetic nanoparticle and magnetic probe

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000031240

Enrollment

180

Registered

2018-02-09

Start date

2016-10-18

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer

Interventions

On the day before surgery or in the morning of the operation day, 1ml a superparamagnetic iron oxide (SPIO) contrast agent are injected on the same side of breast cancer in subcutaneous areola. All

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Primary breast cancer with clinical no lymph node metastasis

Exclusion criteria

Exclusion criteria: 1. Breast cancer recurrence 2. Who had a history of operation of Axilla 3. Post operative status of augmentation mammaplasty 4. Male breast cancer

Design outcomes

Primary

Measure	Time frame
Identification rate	—

Secondary

Measure	Time frame
Safety	—

Countries

Japan

Contacts

Public ContactTomoko Kurita

Nippon Medical School Hospital Department of Breast Surgery

tomoko28@nms.ac.jp03-3822-2131

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026